SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about updates

16 Dec 2025 Evaluate

Akums Drugs and Pharmaceuticals has informed that Maxcure Nutravedics, a wholly-owned subsidiary of Akums Drugs & Pharmaceuticals, has received another order from the Office of the Deputy Commissioner of State Tax, Gujarat, imposing an additional penalty of INR 1,79,55,000/- under Section 129(3) of the CGST Act, 2017, over and above the penalty already disclosed on 15th December, 2025. Details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are provided herein as Annexure-A.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×